Evidence map›Paper›PMID 23357051›Full record

ArticleJournal of immunological methods2013

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Daniel Smrž, Geethani Bandara, Shuling Zhang, Beverly A Mock, Michael A Beaven, Dean D Metcalfe, Alasdair M Gilfillan

Open access · greenAbstract read
In one paragraph

Article in Journal of immunological methods, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Daniel SmržLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1881, Bethesda, MD 20892-1881, USA. daniel.smrz@lfmotol.cuni.cz
Geethani Bandara
Shuling Zhang
Beverly A Mock
Michael A Beaven
Dean D Metcalfe
Alasdair M Gilfillan
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · US

Funding

The Genetics of Susceptibility to Mouse Plasma Cell TumorsZIABC010008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MOCK, BEVERLY · 2009 to 2025
$9.0M
Integrated Signaling Pathways for the Enhancement of Mast Cell ActivationZIAAI000965 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI METCALFE, DEAN D · 2009 to 2018
$5.3M
Critical signaling nodes regulating mast cell releasibility phenotypesZIAAI000967 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI METCALFE, DEAN D · 2009 to 2012
$1.4M
Intramural NIH HHS ZIA AI000967
6 · The paper itself

Abstract

Activation of KIT, by its ligand, stem cell factor (SCF), results in the initiation of signal transduction pathways that influence mast cell survival and proliferation. Activating mutations in KIT have thus been linked to clonal MC proliferation associated with systemic mastocytosis. SCF also modulates MC function by inducing MC chemotaxis and by potentiating antigen (Ag)/IgE-mediated MC degranulation. Thus, mutations in KIT also have the potential to affect these processes in allergic and other mast cell-related diseases. Studies to determine how native and mutated KIT may modulate MC chemotaxis and activation have, however, been limited due to the lack of availability of a suitable functional MC line lacking native KIT which would allow transduction of KIT constructs. Here we describe a novel mouse MC line which allows the study of normal and mutated KIT constructs. These cells originated from a bone marrow-derived mouse MC culture out of which a rapidly dividing mast cell sub-population spontaneously arose. Over time, these cells lost KIT expression while continuing to express functional high affinity receptors for IgE (FcεRI). As a consequence, these cells degranulated in response to Ag/IgE but did not migrate nor show any evidence of potentiation of Ag/IgE degranulation in response to SCF. Retroviral transduction of the cells with a human (hu)KIT construct resulted in surface expression of huKIT which responded to huSCF by potentiation of Ag/IgE-induced degranulation and chemotaxis. This cell line thus presents a novel system to delineate how MC function is modulated by native and mutated KIT and for the identification of novel inhibitors of these processes.

Indexed as

AnimalsAntigensBenzamidesBone Marrow CellsCalciumCell DegranulationCells, CulturedCell SurvivalChemotaxisCytokinesFlow CytometryHumansImatinib MesylateImmunoblottingMast CellsMiceAntigensBenzamidesCalciumCytokinesImatinib MesylatemTOR protein, mousePiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrimidinesReceptors, IgEStem Cell FactorTOR Serine-Threonine Kinases

Identifiers

PMID23357051
PMCPMC3602326
OpenAlexW2030342411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.